Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity

Keyphrases

• Signaling Axis 100%
• Tumorigenic Activities 100%
• EFR3A 100%
• PI4KA 100%
• Vulnerability 20%
• KRAS mutation 20%
• Plasma Membrane 20%
• Interactome 20%
• Tumorigenesis 20%
• Therapeutic Potential 20%
• Oncoprotein 20%
• Human Cancer 20%
• Adapter Protein 20%
• Effector Proteins 20%
• Phosphatidylinositol Kinase 20%
• Oncogenic Signaling 20%
• KRAS G12C 20%
• KRAS Signaling 20%
• Clinical Trajectory 20%
• HRAS Gene 20%
• KRAS-mutant Cancer 20%
• Plasma Membrane Signaling 20%
• RAS-GTP 20%
• Antineoplastic 20%
• Phosphatidylinositol-4-phosphate 20%
• NRAS Gene 20%

Biochemistry, Genetics and Molecular Biology

• Carcinogenesis 100%
• KRAS 100%
• Carcinogenic Activity 100%
• Cell Membrane 33%
• Kinase 16%
• Phosphotransferase 16%
• Antineoplastic Activity 16%
• Guanosine Triphosphate 16%
• Interactome 16%
• Phosphatidylserine 16%
• HRAS 16%
• Phosphatidylinositol 16%
• Phosphatidylinositol 4-Phosphate 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Carcinogenesis 100%
• Oncoprotein 25%
• Phosphatidylserine 25%
• Anticarcinogen 25%
• Guanosine Triphosphate 25%
• Phosphatidylinositol Kinase 25%
• Phosphatidylinositol 4 Phosphate 25%